Ellen Holm Nielsen

Corporate Officer/Principal presso University of Southern Denmark

Consumer Services

Health Technology

Profilo

Ellen Holm Nielsen is currently a Principal at the University of California, Berkeley, the University of Copenhagen, the University of Southern Denmark, and Albert Einstein College of Medicine, Inc. She previously worked as a Director at Profylakse ApS.

Posizioni attive di Ellen Holm Nielsen

Società	Posizione	Inizio
University of Southern Denmark	Corporate Officer/Principal	-
University of California, Berkeley	Corporate Officer/Principal	-
Albert Einstein College of Medicine, Inc.	Corporate Officer/Principal	14/08/2009
University of Copenhagen	Corporate Officer/Principal	-

Tutte le posizioni attive di Ellen Holm Nielsen

Precedenti posizioni note di Ellen Holm Nielsen

Società	Posizione	Fine
Profylakse ApS Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations.	Direttore/Membro del Consiglio	22/11/2013

Vedi nel dettaglio l'esperienza di Ellen Holm Nielsen

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ellen Holm Nielsen

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Profylakse ApS Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations.	Health Technology